Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors
- PMID: 28705641
- DOI: 10.1016/j.bmcl.2017.06.069
Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors
Abstract
A series of novel diaryl substituted pyrazolyl 2,4-thiazolidinediones were synthesized via reaction of appropriate pyrazolecarboxaldehydes with 2,4-thiazolidinedione (TZD) and nitrobenzyl substituted 2,4-thiazolidinedione. The resulting compounds were screened in vitro for pancreatic lipase (PL) inhibitory activity. Two assay protocols were performed viz., methods A and B using p-nitrophenyl butyrate and tributyrin as substrates, respectively. Compound 11e exhibited potent PL inhibitory activity (IC50=4.81µM and Xi50=10.01, respectively in method A and B), comparable to that of the standard drug, orlistat (IC50=0.99µM and Xi50=3.72). Presence of nitrobenzyl group at N-3 position of TZD and nature of substituent at para position of phenyl ring at C-3 position of pyrazole ring notably affected the PL inhibitory activity of the tested compounds. Enzyme inhibition kinetics of 11e revealed its reversible competitive inhibition, similar to that of orlistat. Molecular docking studies validated the rationale of pharmacophoric design and are in accordance to the in vitro results. Compound 11e exhibited a potential MolDock score of -153.349kcal/mol. Further, the diaryl pyrazolyl wing exhibited hydrophobic interactions with the amino acids of the hydrophobic lid domain. Moreover, the carbonyl group at 2nd position of the TZD ring existed adjacent to Ser 152 (≈3Å) similar to that of orlistat. A 10ns molecular dynamics simulation of 11e-PL complex revealed a stable binding conformation of 11e in the active site of PL (Maximum RMSD≈3Å). The present study identified novel thiazolidinedione based leads with promising PL inhibitory activity. Further development of the leads might result in potent PL inhibitors.
Keywords: Knoevenagel; Molecular modelling; Obesity; Orlistat; Pancreatic lipase; Pyrazole; Thiazolidinedione; pH indicator.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Design, synthesis and biological evaluation of N-substituted indole-thiazolidinedione analogues as potential pancreatic lipase inhibitors.Chem Biol Drug Des. 2021 Jul;98(1):49-59. doi: 10.1111/cbdd.13846. Epub 2021 May 2. Chem Biol Drug Des. 2021. PMID: 33864339
-
Computational approaches for the discovery of natural pancreatic lipase inhibitors as antiobesity agents.Future Med Chem. 2020 Apr;12(8):741-757. doi: 10.4155/fmc-2019-0284. Epub 2020 Mar 26. Future Med Chem. 2020. PMID: 32212943 Review.
-
Design, synthesis, biological evaluation, and molecular modeling studies of rhodanine derivatives as pancreatic lipase inhibitors.Arch Pharm (Weinheim). 2019 Oct;352(10):e1900029. doi: 10.1002/ardp.201900029. Epub 2019 Aug 13. Arch Pharm (Weinheim). 2019. PMID: 31407389
-
2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018).Mini Rev Med Chem. 2019;19(7):591-598. doi: 10.2174/1389557518666181026092029. Mini Rev Med Chem. 2019. PMID: 30968766 Review.
-
Synthesis, evaluation and molecular modelling studies of 2-(carbazol-3-yl)-2-oxoacetamide analogues as a new class of potential pancreatic lipase inhibitors.Bioorg Med Chem. 2017 Jan 15;25(2):609-620. doi: 10.1016/j.bmc.2016.11.031. Epub 2016 Nov 18. Bioorg Med Chem. 2017. PMID: 27908755
Cited by
-
Exploring Aurone Derivatives as Potential Human Pancreatic Lipase Inhibitors through Molecular Docking and Molecular Dynamics Simulations.Molecules. 2020 Oct 13;25(20):4657. doi: 10.3390/molecules25204657. Molecules. 2020. PMID: 33066044 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous